217 related articles for article (PubMed ID: 17728024)
41. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
[TBL] [Abstract][Full Text] [Related]
42. Targeting of nucleoprotein to chemokine receptors by DNA vaccination results in increased CD8(+)-mediated cross protection against influenza.
Baranowska M; Hauge AG; Hoornaert C; Bogen B; Grødeland G
Vaccine; 2015 Dec; 33(49):6988-96. PubMed ID: 26387432
[TBL] [Abstract][Full Text] [Related]
43. Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness.
Vemula SV; Ahi YS; Swaim AM; Katz JM; Donis R; Sambhara S; Mittal SK
PLoS One; 2013; 8(4):e62496. PubMed ID: 23638099
[TBL] [Abstract][Full Text] [Related]
44. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
45. Cross-protective potential of anti-nucleoprotein human monoclonal antibodies against lethal influenza A virus infection.
Fujimoto Y; Tomioka Y; Takakuwa H; Uechi GI; Yabuta T; Ozaki K; Suyama H; Yamamoto S; Morimatsu M; Mai LQ; Yamashiro T; Ito T; Otsuki K; Ono E
J Gen Virol; 2016 Sep; 97(9):2104-2116. PubMed ID: 27260213
[TBL] [Abstract][Full Text] [Related]
46. Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity.
Ohba K; Yoshida S; Zahidunnabi Dewan M; Shimura H; Sakamaki N; Takeshita F; Yamamoto N; Okuda K
Vaccine; 2007 May; 25(21):4291-300. PubMed ID: 17403560
[TBL] [Abstract][Full Text] [Related]
47. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.
Schmeisser F; Adamo JE; Blumberg B; Friedman R; Muller J; Soto J; Weir JP
Vaccine; 2012 May; 30(23):3413-22. PubMed ID: 22465746
[TBL] [Abstract][Full Text] [Related]
48. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
[TBL] [Abstract][Full Text] [Related]
49. Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge.
Major D; Chichester JA; Pathirana RD; Guilfoyle K; Shoji Y; Guzman CA; Yusibov V; Cox RJ
Hum Vaccin Immunother; 2015; 11(5):1235-43. PubMed ID: 25714901
[TBL] [Abstract][Full Text] [Related]
50. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
Sandbulte MR; Jimenez GS; Boon AC; Smith LR; Treanor JJ; Webby RJ
PLoS Med; 2007 Feb; 4(2):e59. PubMed ID: 17298168
[TBL] [Abstract][Full Text] [Related]
51. Vaccinia-based influenza vaccine overcomes previously induced immunodominance hierarchy for heterosubtypic protection.
Kwon JS; Yoon J; Kim YJ; Kang K; Woo S; Jung DI; Song MK; Kim EH; Kwon HI; Choi YK; Kim J; Lee J; Yoon Y; Shin EC; Youn JW
Eur J Immunol; 2014 Aug; 44(8):2360-9. PubMed ID: 24825439
[TBL] [Abstract][Full Text] [Related]
52. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
Ninomiya A; Imai M; Tashiro M; Odagiri T
Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses.
Lapuente D; Ruzsics Z; Thirion C; Tenbusch M
Vaccine; 2018 May; 36(19):2712-2720. PubMed ID: 29628150
[TBL] [Abstract][Full Text] [Related]
54. The role of the N-terminal caspase cleavage site in the nucleoprotein of influenza A virus in vitro and in vivo.
Lipatov AS; Yen HL; Salomon R; Ozaki H; Hoffmann E; Webster RG
Arch Virol; 2008; 153(3):427-34. PubMed ID: 18058063
[TBL] [Abstract][Full Text] [Related]
55. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
56. Recombinant vesicular stomatitis virus expressing influenza nucleoprotein induces CD8 T-cell responses that enhance antibody-mediated protection after lethal challenge with influenza virus.
Barefoot BE; Sample CJ; Ramsburg EA
Clin Vaccine Immunol; 2009 Apr; 16(4):488-98. PubMed ID: 19244472
[TBL] [Abstract][Full Text] [Related]
57. Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1.
Lambe T; Carey JB; Li Y; Spencer AJ; van Laarhoven A; Mullarkey CE; Vrdoljak A; Moore AC; Gilbert SC
Sci Rep; 2013; 3():1443. PubMed ID: 23485942
[TBL] [Abstract][Full Text] [Related]
58. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.
Antrobus RD; Coughlan L; Berthoud TK; Dicks MD; Hill AV; Lambe T; Gilbert SC
Mol Ther; 2014 Mar; 22(3):668-674. PubMed ID: 24374965
[TBL] [Abstract][Full Text] [Related]
59. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.
Carragher DM; Kaminski DA; Moquin A; Hartson L; Randall TD
J Immunol; 2008 Sep; 181(6):4168-76. PubMed ID: 18768874
[TBL] [Abstract][Full Text] [Related]
60. Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella vaccine.
Ashraf S; Kong W; Wang S; Yang J; Curtiss R
Vaccine; 2011 May; 29(23):3990-4002. PubMed ID: 21466806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
